During the chemotherapy phase, sufferers received up to six cycles consisting of 21 days. The median duration of treatment in the sorafenib plus gemcitabine/cisplatin group was 17 weeks and 18 weeks in the placebo plus gemcitabine/cisplatin group. There is no significant improvement in OS among individuals who received sorafenib. The median PFS was 6.0 months in the sorafenib plus gemcitabine/cisplatin group and 5.5 months in the placebo arm, but this difference did not reach statistical significance. The median TTP was 6.1 months in the sorafenib-treated patients and 5.5 months among those receiving gemcitabine/cisplatin and placebo, a 27 percent difference that was statistically significant.‘The common Medicare beneficiary provides about 33 Advantage programs to chose out of this year. Furthermore to basic Medicare coverage, many offer extras such as vision, dental or hearing insurance. Insurers have developed more than 2,000 Medicare Advantage plans serving a lot more than 11 million people, based on the Kaiser Family Foundation. All these options include their own sets of variables like different deductibles, premiums and co-insurance.’ The AP answers queries and provides advice on selecting a plan by looking at factors such as premiums and hospitalization insurance coverage . This content is usually republished with kind permission from our close friends at The Kaiser Family Foundation.